The in vitro antibacterial activity of piperacillin and cefuroxime against 180 isolates of cephalothin-resistant Enterobacteriaceae and of piperacillin against 46 isolates of Pseudomonas aeruginosa was determined. Amikacin, gentamicin, carbenicillin, cefoxitin, and cefamandole were included for comparison. The activities of piperacillin and carbenicillin against Enterobacteriaceae were comparable. Piperacillin was appreciably more active against Pseudomonas than carbenicillin and was equivalent in activity to arnikacin on a weight basis. The following beta-lactam agents were the most active against the indicated organisms (in parentheses): cefoxitin (indole-positive Proteus spp.), cefuroxime and cefoxitin, (Klebsiella spp.), piperacillin (Enterobacter spp.), cefuroxime and cefoxitin (E. coli), piperacillin and cefoxitin (Serratia spp.), and cefoxitin (Providencia spp.). Amikacin inhibited 98% of Enterobacteriaceae at clinically achievable serum levels.
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Infections due to multiply drug-resistant gram-negative bacilli constitute a major problem in medical therapeutics. Gentamicin has been a mainstay of therapy in cases of cephalothin-resistant gram-negative bacillary infection, but its widespread use has resulted in increasing bacterial resistance (7) .
The occurrence in our hospital of Pseudomonas aeruginosa and Enterobacteriaceae resistant to gentamicin or various beta-lactam antibiotics, or both, prompted this study of the in vitro susceptibility of multiply drug-resistant, gram-negative bacilli to piperacillin, cefuroxime, carbenicillin, cefoxitin, cefamandole, gentamicin and amikacin.
Piperacillin (T-1220), a new aminobenzyl penicillin, has in vitro activity against many Enterobacteriaceae and P. aeruginosa (10) . Cefuroxime, a semisynthetic cephalosporin, is a new agent that is active against many cephalothinresistant, gram-negative bacilli (8, 11 (4) . A miimum inhib--128 tg/m1. All gentaxnci-resistant Klebsiella itory concentration of _128 jig/ml was chosen to in-spp., Enterobacter spp., Providencia spp., and dicate susceptibility to piperaciUin (1) .
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The activity of cefoxitin was equal to or with 5% defibrinated sheep blood was subjected to greater than that of cefuroxime and cefamandole repetitive freeze-thawing, and the extracted fluid was against all genera of Enterobacteriaceae tested analyzed by atomic absorption spectrophotometry to except Enterobacter (Tables 2 and 4 (Tables 2 and 4 ). The activity of cefuroxime against cephalothin-resistant Kiebsiella spp., Enterobacter spp., Providencia spp., and E. coli is significant; in vivo studies and additional in vitro investigation seem indicated.
Amikacin inhibited 176 of 180 Enterobacteriaceae tested at clinically achievable serum levels and is currently the drug of choice in our institution for initial therapy of serious nosocomial gram-negative bacillary infections. The above data, however, indicate that some of the newer beta-lactam antibiotics also have significant activity against multiply drug-resistant gram-negative bacilli. The use of one of these agents rather than an aminoglycoside for the treatment of such infections would be expected to reduce the incidence of drug-related nephrotoxicity and to eliminate the risk of ototoxicity. If cefuroxime, cefoxitin, or cefamandole were released for clinical use, a change in hospital laboratory susceptibility testing might become necessary because of the different degrees of activity of each of these agents against isolates of various genera of Enterobacteriaceae noted in this and other studies (8, 12) .
Piperacillin was active against many of the cephalothin-resistant, gentamicin-susceptible Enterobacteriaceae. Clinical trials will be necessary to determine whether the development of resistance in vivo, as occurs with carbenicillin, will be a significant problem with the use of piperacillin as a single therapeutic agent.
Multiply drug-resistant P. aeruginosa currently represent a serious clinical problem in our hospital (6) . In this study, 32% of selected gentamicin-resistant P. aeruginosa were resistant to amikacin, and 46% were resistant to carbeni- cillin at clinically achievable levels; a previous study demonstrated that 81% of gentamicin-resistant P. aeruginosa in our institution were also resistant to tobramycin (6) . Only 11% of gentamicin-resistant P. aeruginosa were resistant to piperacillin at clinically achievable serum concentrations.
In vitro and in vivo studies of piperacilin, in combination with an aminoglycoside and as a single agent, should be done to evaluate the activity of this new antibiotic, particularly against multiply drug-resistant P. aeruginosa.
